Concepedia

Publication | Open Access

Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic Leukemia

DOIFull Paper Access

19

Citations

32

References

2019

Year

Linyu Yang, Qiang Qiu, Minghai Tang, Fang Wang, Yuyao Yi, Dongni Yi, Zhuang Yang, Zejiang Zhu, Shoujun Zheng, Jianhong Yang,
Clinical Cancer Research

Abstract

Purinostat mesylate provides a new therapeutic strategy for patients with Ph<sup>+</sup> B-ALL, including those who relapse after TKI treatment.

References

YearCitations

Page 1